Niraparib (CAS Registry Number: 1038915-60-4, marketed in various salt forms including Niraparib Tosylate Monohydrate) represents an essential milestone in target-specific oncology therapeutics. As a potent, highly selective oral poly (ADP-ribose) polymerase (PARP-1 and PARP-2) inhibitor, Niraparib induces synthetic lethality in tumor cells carrying homologous recombination repair deficiencies (HRD), particularly those exhibiting mutated BRCA1 and BRCA2 genes. For global pharmaceutical procurement teams, CROs, and generic formulators, sourcing high-purity Niraparib API from an established Wholesale Niraparib Factory & Company is a pivotal factor in guaranteeing drug bioequivalence, clinical stability, and regulatory approval.
Niraparib's chemical chemical structure—2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide—features a chiral piperidine core coupled with an indazole carboxamide pharmacophore. Unlike earlier PARP inhibitors, Niraparib displays unique pharmacokinetic properties characterized by deep tissue distribution, prolonged intracellular retention, and superior blood-brain barrier permeability in pre-clinical oncological models. Mechanistically, Niraparib traps PARP-1 and PARP-2 complexes at sites of single-strand DNA breaks, preventing enzymatic auto-PARylation and blocking single-strand lesion repair. When unrepaired single-strand breaks encounter replication forks during the S-phase, double-strand breaks (DSBs) are generated. In homologous recombination deficient (HRD) tumors, these DSBs cannot be accurately repaired, precipitating genomic instability and selective cell death.
The global demand for PARP inhibitors continues on a rapid growth trajectory, driven by expanded clinical indications in maintenance therapies for recurrent epithelial ovarian, fallopian tube, primary peritoneal, and metastatic castration-resistant prostate cancer (mCRPC).
Synthesizing commercial-grade Niraparib API involves multi-step asymmetric chemistry demanding hyper-rigorous process controls to prevent structural degradation and isomer impurities.
Modern industrial synthesis of Niraparib tosylate monohydrate relies on specialized asymmetric hydrogenation and Suzuki-Miyaura cross-coupling reactions. As a leading Wholesale Niraparib Factory, our manufacturing facilities implement real-time Process Analytical Technology (PAT) to monitor critical process parameters (CPPs) and critical quality attributes (CQAs).
The standard synthetic route originates from 2-nitro-6-substituted benzoic acid derivatives. Following functional group transformation to yield the indazole scaffold, the intermediate undergoes coupling with a chiral 3-(4-halophenyl)piperidine precursor. The resulting compound is salt-formed with p-toluenesulfonic acid under controlled aqueous-organic solvent ratios to crystallize the pure monohydrate form. Our quality control laboratories enforce rigorous testing parameters aligned with international ICH Q3A/B guidelines:
Replacing legacy noble metal catalysts with recyclable, earth-abundant organocatalytic systems to reduce raw material cost overhead.
Transitioning batch indazole coupling into continuous microfluidic reactors, expanding volumetric yield by 35% while eliminating hazardous hotspots.
Implementation of eco-friendly bio-based solvents, eliminating toxic chlorinated hydrocarbons across all extraction and wash stages.
Real-time inline NIR spectroscopy coupled with machine learning model predictors to guarantee batch-to-batch polymorphic uniformity.
We provide extensive technical packages including Drug Master Files (DMF), CEP filings, ASMF documentation, and complete analytical method validation reports (ICH Q2(R1)) to support client registrations worldwide.
Equipped with jet-milling and controlled crystallization technologies, we offer custom micronization services tailored to meet specified bulk density, tapped density, and dissolution profile requirements.
Full cold-chain logistics management with real-time temperature tracking and desiccant-shielded tamper-evident packaging ensures API structural stability throughout international transit.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
